EndoSphere

About EndoSphere

EndoSphere Inc. is a medical technology company established in 2006, focused on developing less-invasive treatments for metabolic diseases like obesity and type 2 diabetes. The company was co-founded by Dr. Kenneth Binmoeller, a renowned gastroenterologist and entrepreneur. Dr. Binmoeller is a prolific researcher with over 300 publications and previously founded Xlumena, a company acquired by Boston Scientific for $75 million in 2015. His background in advanced endoscopy and device invention directly led to the creation of EndoSphere, aiming to provide a safer, physiologic alternative to existing obesity treatments.

The company's core business revolves around its proprietary "Endo-Metabolic" devices, specifically the SatiSphere system. This technology is designed as a non-surgical solution for weight loss, targeting the duodenum, which it identifies as the body's "metabolic control center". The business model appears to be centered on the sale of these medical devices to healthcare providers and hospitals for use in bariatric and gastroenterology practices. The target clients are patients struggling with obesity who are seeking alternatives to bariatric surgery or pharmaceuticals.

The SatiSphere device is a temporary, removable implant inserted endoscopically into the duodenum during a brief outpatient procedure. Made of a pre-formed memory wire, it conforms to the natural shape of the duodenum without being attached to the body. Its function is to slow the passage of food, which stimulates nerve receptors in the duodenal walls. This process amplifies the body's natural satiety feedback loops, triggering hormones that regulate appetite, making the patient feel full sooner and for a longer duration. The device is incisionless, reversible, and repeatable. Early clinical trials showed patients experiencing an average excess weight loss of 12 percent within the first month. The company secured a CE Mark in Europe, indicating compliance with health and safety standards for sale in the European Economic Area.

Since its founding, EndoSphere has raised significant capital to fund product development and clinical trials. It completed an oversubscribed Series A financing round in June 2011, led by Broadline Capital. By 2012, the company had attracted $3.1 million in a Series B round involving investors such as North Coast Angel Fund and Queen City Angels. Total funding has been reported at amounts between $6.45 million and $18.4 million over several rounds. The company also holds a robust intellectual property portfolio, with numerous U.S. and international patents for its technology, including U.S. Patent 7,931,693 for a "Method and Apparatus for Reducing Obesity".